NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on NRx Pharmaceuticals, Inc. (NRXP) click here.